insights_auto
Miks on OPHLY langenud? 2,31%?
Uurige põhjalikumaltchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,65Â $
arrow_downward
−2,31%(−0,11) 1 p
14. okt, 16:00:00 GMT −4 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse OPHLY põhistatistika genereerimine…
Ava
4,71Â $
Kõrge
4,93Â $
Madal
4,63Â $
Turu kapit.
1,17Â trln
Keskm. maht
62,09Â tuh
Maht
35,04Â tuh
52 näd kõrgeim
5,75Â $
52 näd madalaim
3,82Â $
Beeta
0,21
Käibivad aktsiad
1,50Â mld
Töötajate arv
4Â tuh
Ava
4,71Â $
Kõrge
4,93Â $
Madal
4,63Â $
Turu kapit.
1,17Â trln
Keskm. maht
62,09Â tuh
Maht
35,04Â tuh
52 näd kõrgeim
5,75Â $
52 näd madalaim
3,82Â $
Beeta
0,21
Käibivad aktsiad
1,50Â mld
Töötajate arv
4Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Ärileht
·
1 päeva eest
Mida sa investeerides tegelikult ostad? Paljude lemmik naudib erakordselt head aega
www.marketscreener.com
·
27 minuti eest
OpenWorld (NASDAQ: OPNW) Signs Term Sheet to Finance Solar-Powered, Distributed AI Computing Network Initially Integrated with Residential Battery Storage with Tokenized Financing Program of up to $1 Billion
GlobeNewswire
·
29 minuti eest
AZIO AI Holdings Inc. (NASDAQ: AZIO) Building Solution to
CNN
·
2 tunni eest
Global tech selloff deepens as enthusiasm for AI stocks wobbles
Profiil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Teave üksuse Ono Pharmaceutical ADR Representing 1/3rd Ord Shs kohta
TegevjuhtGyo Sagara | Gyo Sagara
Töötajad4,21 tuh
Asutatud1717
PeakontoridÅŒsaka, ÅŒsaka prefektuur, Jaapan
Sektor-
Veebisaitono-pharma.com